Neoadjuvant combination biotherapy with ipilimumab (3 or 10 mg/kg) and high-dose IFN-α2B in patients with locally/regionally advanced/recurrent melanoma: a randomized safety, efficacy and biomarker study. The gene discussed is IFNA2; the disease is melanoma.